Research

Hormonal

Acarbose, an alpha-glucosidase inhibitor, reduces the risk of cardiovascular disease and postprandial hypotension by slowing carbohydrate digestion and absorption.

For high-risk patients with impaired glucose tolerance, Acarbose (50-100mg at breakfast) can significantly reduce cardiovascular risk and postprandial hypotension by slowing carbohydrate absorption.

GoodSupportsHIGH confidence
Acarbose has been also shown to reduce the development of diabetes and also CVD in the STOP NIDDM (Study to Prevent Non-Insulin-Dependent Diabetes Mellitus) trial by 49%
Ayan Agarwal et al. · International Journal on Heart and Vascular system · 2021

Why this rating

Based on the STOP NIDDM trial and meta-analyses cited.

Source

The Glycemic Index, Postprandial Hypotension and Cardiovascular Disease

Ayan Agarwal et al. · International Journal on Heart and Vascular system · 2021

DOI 10.51626/ijhvs.2021.01.00003

narrative_reviewCited 2×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →